TherapeuticsMD (TXMD) Proxy Filing summary

Executive summary

• Annual meeting scheduled for December 15, 2025, to be held virtually for shareholder participation.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of four directors to serve until the next annual meeting or until successors are qualified.

• Advisory vote to approve executive compensation for the fiscal year ended December 31, 2024.

• Advisory vote on the frequency of future say-on-pay votes, with the board recommending an annual vote.

• Ratification of Berkowitz Pollack Brant Advisors + CPAs, LLP as independent auditor for the fiscal year ending December 31, 2025.

• Proposal to amend the Articles of Incorporation to increase authorized common stock to 640,000,000 shares.

Board of directors and corporate governance

• Board recommends voting for all director nominees and for all proposals except the frequency of say-on-pay, where annual is recommended.